CtrlK
Viracta Therapeutics
VIRX37
$0.07arrow_drop_down53.86%-$0.08
Penny Stock
VIRX37
$0.07
arrow_drop_down53.86%Performance History
There's no data available for performance history chart
| Key Stats | |
|---|---|
| Open | $0.08 |
| Prev. Close | $0.15 |
| EPS | -1.10 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $914.11K |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 0.05 | 0.15 |
| 52 Week Range | 0.05 | 1.31 |
| Ratios | |
|---|---|
| P/B Ratio | 3.00 |
| Revenue | - |
| Operating M. % | 0.00% |
| Earnings | $0.00 |
| Earnings Growth % | -3.78% |
| EBITDA Margin % | - |
| ROE % | -370.13% |
| EPS | -1.10 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Predicted: 15 seconds ago
info
Analyzed by 6 Wall Street experts, Moleculin Biotech 's 12-month projections average at $16.33, spanning from a high of $40.00 to a low of $3.00. This signifies an 1,291.25% shift from the current price of $1.16.
Analyst Ratings
Buy
| Buy | 2 | 66.67% | |
|---|---|---|---|
| Hold | 1 | 33.33% | |
| Sell | 0 | 0.00% |
•Ratings from: March•
Last updated: 15 seconds ago
•Total: 3info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.
Viracta Therapeutics (VIRX)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Mark Andrew Rothera
- Headquarters
- Cardiff-by-the-Sea
- Employees
- 41
- Exchange
- NASDAQ
Keep an eye on Viracta Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.